IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
The company plans to use the funds raised from the net proceeds to repay or prepay certain loans
FineCross M3 empowers physicians to perform safer PCI procedures, helping improve outcomes in patients with challenging coronary anatomies
The new algorithm will be introduced as part of Roche’s CKD Algorithm Panelon thenavify Algorithm Suite
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
Subscribe To Our Newsletter & Stay Updated
